科兴制药(688136.SH)：GB10注射液临床试验注册申请获得受理

Core Viewpoint - The acceptance of the clinical trial application for "GB10 Injection" by the National Medical Products Administration marks a significant advancement in the company's innovative drug development process [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., has received the acceptance notice for the clinical trial application of "GB10 Injection" [1] - This acceptance is a crucial step in the company's dual-antibody research and development strategy based on its proprietary technology platform [1] Group 2: Market Implications - Successful development and future market launch of the drug could provide a more diverse product offering to meet market demand [1] - This development is expected to enrich the company's product portfolio and enhance its market competitiveness [1]